Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Lantheus Holdings, Inc.

Capitalization 6.51B 0 0 0 0 0 0 0 0 0 0 0 0 P/E ratio 2026 *
25x
P/E ratio 2027 * 19.6x
Enterprise value 6.26B 0 0 0 0 0 0 0 0 0 0 0 0 EV / Sales 2026 *
4.27x
EV / Sales 2027 * 3.59x
Free-Float
88.11%
Yield 2026 *
-
Yield 2027 * -
1 day-0.96%
1 week+2.97%
Current month+0.72%
1 month+7.47%
3 months+37.83%
6 months+60.61%
Current year+50.28%
1 week 95
Extreme 95
104
1 month 91.65
Extreme 91.65
104
Current year 63.37
Extreme 63.37
104
1 year 47.25
Extreme 47.25
104
3 years 47.25
Extreme 47.25
126.89
5 years 22.2
Extreme 22.2
126.89
10 years 2.51
Extreme 2.51
126.89
Manager TitleAgeSince
Chief Executive Officer 66 2025-12-31
Director of Finance/CFO 60 2018-09-20
Chief Tech/Sci/R&D Officer - 2015-12-31
Director TitleAgeSince
Director/Board Member 80 2012-04-30
Chairman 66 2024-02-29
Director/Board Member 61 2016-12-31
Date Insider Type Main position Quantity % Market Cap.
May. 13Free

Director

4,137 0.0064%
May. 13Free

Director

4,137 0.0064%
May. 13Free

Director

4,137 0.0064%
Change 5d. change 1-year change 3-years change Capi.($)
-0.96%+2.97%+22.64%+12.65% 6.57B
-0.57%-3.29%+159.86%+283.22% 16.66B
-0.69%+1.19%-40.70%-21.43% 9.92B
+0.56%-3.95%-28.95%-20.48% 5.16B
-2.12%-1.88% - - 4.66B
0.00%+5.02%-23.69%-27.48% 4.37B
-3.83%-12.62%+80.53%+70.86% 4.37B
-5.99%-1.39%+209.77%-46.28% 3.94B
-2.89%-6.01%-22.27%-44.31% 2.62B
+1.40%-0.76%-38.06%-55.23% 1.38B
Average -1.51%-0.65%+35.46%+16.84% 5.97B
Weighted average by Cap. -1.27%-0.76%+58.59%+78.13%

Financials

2026 *2027 *
Net sales 1.47B 0 0 0 0 0 0 0 0 0 0 0 0 1.66B 0 0 0 0 0 0 0 0 0 0 0 0
Net income 256M 0 0 0 0 0 0 0 0 0 0 0 0 330M 0 0 0 0 0 0 0 0 0 0 0 0
Net Debt -250M -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -546M -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0
Logo Lantheus Holdings, Inc.
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. Its product categories include oncology, neurology, cardiology, and strategic partnerships and others. Its products include PYLARIFY, Neuraceq, and DEFINITY. PYLARIFY TruVu is indicated for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy, or suspected recurrence based on elevated serum prostate-specific antigen (PSA). Neuraceq is an Alzheimer's disease radiodiagnostic. Its commercial products are used by cardiologists, internists, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists across a range of clinical care settings. Its diagnostic products provide information that enables healthcare professionals (HCPs) to better detect, characterize, or rule out diseases.
Employees
1,193
Date Price Change Volume
26-06-08 100.01 $ -0.96% 751,533
26-06-05 100.98 $ -1.79% 746,257
26-06-04 102.82 $ +2.56% 826,297
26-06-03 100.25 $ +4.10% 1,082,232
26-06-02 96.30 $ -0.85% 1,029,855
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
100.01USD
Average target price
105.23USD
Spread / Average Target
+5.22%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LNTH Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
BENEFIT NOW